Home › Funds › Parkman Healthcare Partners LLC › ALNY
Parkman Healthcare Partners LLC position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Parkman Healthcare Partners LLC reported holding 35,159 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$8.7M, representing 0.78% of its reported portfolio and ranking #50 among its reported holdings. Parkman Healthcare Partners LLC has disclosed ALNY holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's ALNY position evolved
Parkman Healthcare Partners LLC first disclosed a stake in ALNY in Q3 2024 at 25,485 shares (US$7.0M). The position peaked in Q3 2025 at 87,690 shares, worth US$40.0M. Across 9 filings, Parkman Healthcare Partners LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 35,159 shares valued at US$8.7M — a reduction of -15,513 shares quarter over quarter.. Notable position changes include a 52% increase in Q4 2024 (shares rose 15% over the following quarter), a 78% increase in Q1 2025 (shares rose 20% over the following quarter), a 88% increase in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 25.48K | $7.01M | New |
| Q4 2024 | 38.67K | $9.10M | Add |
| Q1 2025 | 68.94K | $18.61M | Add |
| Q2 2025 | 92.34K | $30.11M | Add |
| Q3 2025 | 87.69K | $39.99M | Reduce |
| Q4 2025 | 47.70K | $18.97M | Reduce |
| Q1 2026 | 26.92K | $8.91M | Reduce |
| Q2 2026 | 50.67K | $15.25M | Add |
| Q3 2026 | 35.16K | $8.68M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$597.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 2.42M sh · $597.40M · Q3 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held ALNY?
Parkman Healthcare Partners LLC has disclosed ALNY holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Parkman Healthcare Partners LLC's current position in ALNY?
As of Q3 2026, Parkman Healthcare Partners LLC holds 35.16K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $8.68M, representing 0.78% of its reported portfolio and ranking #50.
Has Parkman Healthcare Partners LLC been buying or selling ALNY?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC reduced its position in ALNY. The position peaked in Q3 2025 at 87.69K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.